2022 News

Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)

Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development. This nomination deci...

Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat...

Biorelate and Copyright Clearance Centre announce strategic integration

Manchester, UK.  Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), have announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly ar...

From our portfolio

Rinicare

Digital Healthcare Technology

Rinicare is an intelligent medical device and software company developing and commercialisin...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email